the Effects of Platelet-Rich Plasma on Postoperative Complications After Meningomyelocele

January 24, 2023 updated by: Özkan Arabaci, Yuzuncu Yıl University

A Randomized Trial of the Effects of Platelet-Rich Plasma on Postoperative Complications After Meningomyelocele Sac Repair

Introduction: Meningomyelocele is a common congenital neural tube defect. To reduce complications, early surgery and a multidisciplinary approach is needed. In this study, the investigators administered platelet-rich plasma (PRP) to newborns with meningomyelocele following corrective surgery to minimize cerebrospinal fluid (CSF) leakage and accelerate the healing of the immature pouch tissue. The investigators compared these with a control group that did not receive PRP.

Patients and Methods: Of the 40 newborns who were operated on with the diagnosis of meningomyelocele, 20 patients received PRP after surgical repair, and 20 were followed up without PRP. In the PRP group, 10 of the 20 patients underwent primary defect repair, the other 10 underwent flap repair. In the group that did not receive PRP, primary closure was performed in 14 patients and flap closure in six.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Introduction Meningomyelocele (MMC), a form of spina bifida, is the most common congenital anomaly of the central nervous system. It occurs in the first four weeks of pregnancy when the neural tube of the embryo fails to close. Neural tube defects may result in hydrocephalus, hindbrain herniation, and exposure to toxins in the amniotic fluid, with potential morbidity and mortality (1). Both environmental and genetic factors contribute to the etiology of MMC. The risk of MMC is increasing in the events of maternal exposure to valproate, alcohol, carbamazepine, or isotretinoin; high fever; malnutrition, especially folate or B12 deficiency, diabetes mellitus, or obesity during pregnancy (2). About 1,427 babies are born with spina bifida each year in the United States (1 in 2,758 births). Lower socioeconomic status and older maternal age are associated with higher neural tube defect incidence. The recurrence rate in subsequent pregnancies is about 2% to 3% (3). More than 80% of babies born with MMC require a ventriculoperitoneal shunt for hydrocephalus decompression (4). In 39% of the patients, functional motor deficits are at the affected level or higher, and more than half of these have functional motor deficits two levels higher than the affected level (5). The purpose of early closure of MMC defects is to preserve neural tissue function and prevent sepsis.

Platelet-rich plasma (PRP) is an autologous concentration of human platelets obtained from venous blood through proper centrifugation. It contains several growth factors including platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), platelet-derived factor 4 (PF-4), insulin-like growth factor (IGF-1), and transforming growth factor-beta (TGF-b) (6). There are approximately 150-400 10³/mm³ platelets in the blood and PRP contains between four and seven times this amount (7). When whole blood is collected from a patient for the generation of PRP, an anticoagulant is added. This usually contains citrate and disrupts the coagulation cascade by binding to calcium ions (8). PRP is used in orthopedic indications, wound healing, facial rejuvenation, hair restoration, and other conditions in which tissue renewal is central. The use of PRP for surgical and non-surgical wounds is advantageous, especially in patients with poor wound healing, poor blood supply, and slow cell turnover, and in cases where rapid healing is required.

In this study, we assessed whether the administration of PRP during the MMC pouch repair procedure can improve infant outcomes. This was measured by its ability to reduce CSF leakage, meningitis, local infection, skin necrosis, wound dehiscence, and hydrocephalus, and to accelerate the healing of the underdeveloped pouch tissue. These outcomes were compared with those of an MMC control group who did not receive PRP during surgery.

Materials and Methods This study included 40 infants with a diagnosis of MMC who were operated on at our neurosurgery clinic between February 2020 and May 2021. PRP was administered to 20 of the patients and 20 were followed up without PRP. All babies were born at term and fed with breast milk. All infants in the study were followed up in the neonatal intensive care unit. The mean birth weight was 2990 grams. In the PRP group, 10 of the 20 patients underwent primary defect repair and 10 underwent flap repair. In the non-PRP group, 14 patients underwent primary closure and six underwent flap closure. All operations were performed under general anesthesia. Blood was taken from each patient and the platelets were separated by centrifugation at 3200 rpm for five min in a 2 cc whole blood centrifuge device. The plasma was separated with the buffy coat layer. During MMC sac repair, a neural plate was formed and the dura was then made using opposing flaps from the fascia. After hemostasis was achieved, the defect was repaired and PRP was applied from the wound edge. The prepared PRP was applied to the dura and pouch repair and under the skin flap wound line.

Descriptive statistics were expressed as means, standard deviations, medians, ranges, frequencies, and ratios. The distribution of variables was measured with the Kolmogorov-Smirnov test. Independent sample t-tests and Mann-Whitney U tests were used for the analysis of quantitative independent data. Chi-square tests were used in the analysis of qualitative independent data, and the Fischer test was used when the chi-square test conditions were not met. Analyses were performed using SPSS 27.0 software.

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Van, Turkey, 65100
        • Van Yuzuncu Yıl Unıversty

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 day to 1 month (CHILD)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Newborn babies born with a meningomyelocele sac

Exclusion Criteria:

  • Newborn babies without a meningomyelocele sac

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: Use of Platelet-Rich Plasma after meningomyelocele sac repair
Paitents treated with platelet-rich plasma injection and treated with according to guidelines
Procedure: Use of Platelet-Rich Plasma after meningomyelocele sac repair
Wound healing with the use of Platelet-Rich Plasma after surgical meningomyelocele pouch repair
Procedure: meningomyelocele sac repair
meningomyelocele sac repair without Platelet-Rich Plasma
ACTIVE_COMPARATOR: Control group of meningomyelocele sac repair
Paitents treated according to guidelines
Procedure: meningomyelocele sac repair
meningomyelocele sac repair without Platelet-Rich Plasma

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Skin Dehicense Occurrence
Time Frame: up to first 14 days after the surgery
Area of surgery has been examined daily for skin dehisence
up to first 14 days after the surgery
Partial Skin Necrosis Occurrence
Time Frame: up to first 14 days after the surgery
Area of surgery has been examined daily for skin necrosis
up to first 14 days after the surgery
CSF Leak Occurrence
Time Frame: up to first 14 days after the surgery
Area of surgery has been examined daily for CSF leakage
up to first 14 days after the surgery
Local Infection Occurrence
Time Frame: up to first 14 days after the surgery
Area of surgery has been examined daily for wound infection
up to first 14 days after the surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hydrocephalus Occurrence
Time Frame: birth to 6 months
Patients had examined as out-patients monthly for 6 months with head circumference documentation and with cranial MRIs
birth to 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Yuzuncu Yıl University

Investigators

  • Study Director: Mehmet Edip Akyol, Ass. Prof, Van Yuzuncu Yıl Unıversty

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 15, 2022

Primary Completion (ACTUAL)

November 15, 2022

Study Completion (ACTUAL)

December 15, 2022

Study Registration Dates

First Submitted

December 9, 2022

First Submitted That Met QC Criteria

January 24, 2023

First Posted (ACTUAL)

February 3, 2023

Study Record Updates

Last Update Posted (ACTUAL)

February 3, 2023

Last Update Submitted That Met QC Criteria

January 24, 2023

Last Verified

January 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • YuzuncuYıl1

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Meningomyelocele/Spina Bifida

Clinical Trials on Use of Platelet-Rich Plasma after meningomyelocele sac repair

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe